September 2022
- Exclusive
- Biotech
Cancer biotech hunts $50m as it kicks off phase-two trial
Aucentra Therapeutics has doubled the size of its capital raise amid interest from investors in its CDK4/6 inhibitor drug.
- Yolanda Redrup
August 2021
Telix Pharma is on the cusp of first US FDA approval
The nuclear medicine company is not only going after the huge US market, it has the equivalent documentations with 17 other countries’ regulators.
- Carrie LaFrenz
July 2021
- Exclusive
- Funding
Australia’s richest families back brain mapping software company
Omniscient Neurotechnology has raised $40 million in series B financing from wealthy individuals, including Will Vicars and Gina Rinehart.
- Carrie LaFrenz
May 2021
Imugene pens global patent licensing deal with LA-based research centre
ASX-listed immuno-oncology company has entered a deal with City of Hope for a novel cancer therapy targeting solid tumours that would otherwise be tough to treat.
- Carrie LaFrenz
September 2020
Biotech Kazia taps Bells for entitlement offer
Sydney-based biotech outfit Kazia Therapeutics is hunting a $25.2 million cash injection, to fund its participation in an international bran cancer study.
- Sarah Thompson, Anthony Macdonald and Tim Boyd
July 2020
Scientists warn of potential wave of COVID-linked brain damage
Doctors say millions could be affected by brain damage and neurological complications after contracting COVID-19.
- Kate Kelland